Literature DB >> 18997034

Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy.

Phil Hyu Lee1, Seok Woo Yong, Young-Sil An.   

Abstract

UNLABELLED: We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy in patients with Parkinson disease dementia (PDD) to determine whether cognitive improvements would be reflected in changes of cerebral metabolic patterns, thus offering insight into the neural substrate of cognitive dysfunction in patients with PDD.
METHODS: We performed a serial PET study before (baseline) and after ChEI therapy on 10 patients with PDD, using statistical parametric mapping. Additionally, covariance analysis was performed to extract regions in which increased change in regional cerebral metabolism correlated significantly with increased Mini-Mental State Examination scores.
RESULTS: The statistical parametric mapping analysis indicated that significantly increased cerebral metabolism after ChEI therapy, compared with at baseline, was most evident in the left angular gyrus extending to the supramarginal area and left superior and middle frontal gyri. Additionally, cerebral metabolism was significantly increased in the right superior frontal and left middle orbitofrontal gyri. In contrast, the right fusiform gyrus showed significantly decreased metabolism after ChEI, compared with at baseline. In the correlation analysis, improvements in Mini-Mental State Examination scores after ChEI treatment were significantly associated with increased cerebral metabolism in the left supramarginal, orbitofrontal, and cingulate areas.
CONCLUSION: Our data suggest that prefrontal and parietal association areas may be relevant structures for the pharmacologic response to ChEI in patients with PDD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997034     DOI: 10.2967/jnumed.108.054668

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.

Authors:  David Garcia-Garcia; Pedro Clavero; Carmen Gasca Salas; Isabel Lamet; Javier Arbizu; Rafael Gonzalez-Redondo; Jose A Obeso; Maria C Rodriguez-Oroz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-08       Impact factor: 9.236

2.  Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease.

Authors:  Tara M Madhyastha; Mary K Askren; Peter Boord; Jing Zhang; James B Leverenz; Thomas J Grabowski
Journal:  Mov Disord       Date:  2015-03-11       Impact factor: 10.338

3.  Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease.

Authors:  Yunqi Xu; Xiaobo Wei; Xu Liu; Jinchi Liao; Jiaping Lin; Cansheng Zhu; Xiaochun Meng; Dongsi Xie; Dongman Chao; Albert J Fenoy; Muhua Cheng; Beisha Tang; Zhuohua Zhang; Ying Xia; Qing Wang
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

4.  Recent imaging advances in the diagnosis and management of Parkinson's disease.

Authors:  David J Brooks; Nicola Pavese
Journal:  F1000 Med Rep       Date:  2009-10-29

Review 5.  Recent advances in PET imaging for evaluation of Parkinson's disease.

Authors:  Chrissa Sioka; Andreas Fotopoulos; Athanassios P Kyritsis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-27       Impact factor: 9.236

Review 6.  Molecular imaging as a guide for the treatment of central nervous system disorders.

Authors:  Euitae Kim; Oliver D Howes; Shitij Kapur
Journal:  Dialogues Clin Neurosci       Date:  2013-09       Impact factor: 5.986

7.  Cholinergic relevant functional reactivity is associated with dopamine responsiveness of tremor in Parkinson's disease.

Authors:  Jingjing Wu; Cheng Zhou; Tao Guo; Xiaojun Guan; Ting Gao; Xueqin Bai; Haoting Wu; Jingwen Chen; Jiaqi Wen; Xiaocao Liu; Luyan Gu; Zhe Song; Min Xuan; Quanquan Gu; Peiyu Huang; Jiali Pu; Baorong Zhang; Xiaojun Xu; Minming Zhang
Journal:  Brain Imaging Behav       Date:  2022-01-01       Impact factor: 3.224

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.